Davis's Drug Guide
elranatamab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
**REMS Drug**
Pronunciation:
el-ra-nat-a-mab
Trade Name(s)
- Elrexfio
Ther. Class.
Pharm. Class.
monoclonal antibodies
T-cell engagers
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Elranatamab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Harriet Lane, www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580013/all/elranatamab.
Vallerand AHA, Sanoski CAC. Elranatamab. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580013/all/elranatamab. Accessed June 26, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Elranatamab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580013/all/elranatamab
Vallerand AHA, Sanoski CAC. Elranatamab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 26]. Available from: https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580013/all/elranatamab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - elranatamab
ID - 3580013
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580013/all/elranatamab
PB - F.A. Davis Company
ET - 20
DB - Harriet Lane
DP - Unbound Medicine
ER -
